Targeted Medical Pharma Selected as one of the “Best Six Stocks” by Wall-Street.com

Recognizing Growth and Market Potential in the Microcap Space 

Los Angeles, January 27, 2014 — Targeted Medical Pharma, Inc. (OTCQB: TRGM) announced today that is has been selected as one of the best six stocks in the microcap space by industry specialist Wall-Street.com, a division of Wall-Street Media Co.

“We have worked very hard to be in a position to gain this type of recognition, and it is an honor to be chosen as one of the best six stocks by the industry specialist Wall-Street.com,” said William Shell, M.D., CEO and Chief Scientific Officer of Targeted Medical Pharma, Inc. “Many of the companies Wall-Street.com ranks in their top 15 percent stand an excellent chance of delivering immense value to their shareholders, and we intend to achieve that goal by continuing to execute our business strategy.”

About Wall-Street.com

Wall-Street.com was established in 1994 as one of the first financial websites dedicated to covering the growing microcap space. Wall-Street.com focuses on providing investors with detailed financial and industry information regarding microcap companies. Wall-Street.com was acquired by Wall-Street Media Co. in 2011.

About Targeted Medical Pharma, Inc.

Targeted Medical Pharma, Inc. is a Los Angeles-based biotechnology company that develops  medical foods for the treatment of chronic disease, including pain syndromes, peripheral neuropathy, hypertension, obesity, sleep and cognitive disorders. The company also develops a line of dietary supplements designed to support health and wellness.  The company manufactures 10 proprietary medical foods, 48 convenience kits and recently launched its first dietary supplement, Clearwayz™.  The products are sold directly to physicians and pharmacies in the U.S. The company also is developing nutrient-based systems for oral stimulation of progenitor stem cells that differentiate into neurons, red blood cells, pituitary hormones including IGF-I.

Forward Looking Statement

This press release may contain forward-looking statements related to Targeted Medical Pharma’s business strategy, outlook, objectives, plans, intentions or goals. The words “may,” “will,” “should,” “plans,” “explores,” “expects,” “anticipates,” “continue,” “estimate,” “project,” “intend,” and similar expressions, identify forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, but their absence does not mean that the statement is not forward-looking. These statements are not guarantees of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult to predict. Actual results could differ materially. Targeted Medical Pharma expressly disclaim any obligation or undertaking to update or revise any forward-looking statement contained herein to reflect any change in the company’s expectations with regard thereto or any change in events, conditions or circumstances upon which any statement is based.

#               #               #

Targeted Medical Pharma Announces Completion of Sales Agreement with Pacific Medical, Inc

Agreement Provides the Company with the Ability to Rapidly Expand Sales and Education Programs

Los Angeles, CA, January 10, 2014 — Targeted Medical Pharma, Inc. (OTCQB: TRGM), reported on the completion of an independent sales agreement with Pacific Medical, Inc., a distributor of durable medical equipment in the United States who specializes in orthopedic, rehabilitation, surgery and sports medicine.

The non-exclusive agreement will allow Targeted Medical Pharma to expand medical food sales and education programs to licensed healthcare professionals in Northern California and Northern Nevada for an initial period of one year. The programs will focus on educating prescribers who are currently treating patients with sleep, pain, obesity, and cognitive disorders about safe, effective, non-narcotic medical food treatment options.

“Pacific Medical is another important new business partner of Targeted Medical Pharma, we are very pleased with the sales contract and believe that Pacific Medical’s stellar reputation for delivering quality products and education programs will help healthcare providers understand the importance of utilizing our medical food products as a first line therapy for mitigating pain and inflammation without the risks associated with narcotic pain medications,” said William Shell, M.D. CEO and Chief Science Officer of Targeted Medical Pharma, Inc. “ We believe that Pacific Medical will help enhance the quality of our sales and education program and increase our market penetration with orthopedic and sports medicine specialists.”

About Targeted Medical Pharma, Inc.

Targeted Medical Pharma, Inc. is a Los Angeles-based biotechnology company that develops  medical foods for the treatment of chronic disease, including pain syndromes, peripheral neuropathy, hypertension, obesity, sleep and cognitive disorders. The company also develops a line of dietary supplements designed to support health and wellness.  The company manufactures 10 proprietary medical foods, and recently launched its first dietary supplement, Clearwayz™.  The products are sold directly to physicians and pharmacies in the U.S. The company also is developing nutrient-based systems for oral stimulation of progenitor stem cells that differentiate into neurons, red blood cells, pituitary hormones including IGF-I.

Forward Looking Statement

This press release may contain forward-looking statements related to Targeted Medical Pharma’s business strategy, outlook, objectives, plans, intentions or goals. The words “may,” “will,” “should,” “plans,” “explores,” “expects,” “anticipates,” “continue,” “estimate,” “project,” “intend,” and similar expressions, identify forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, but their absence does not mean that the statement is not forward-looking. These statements are not guarantees of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult to predict. Actual results could differ materially. Targeted Medical Pharma expressly disclaim any obligation or undertaking to update or revise any forward-looking statement contained herein to reflect any change in the company’s expectations with regard thereto or any change in events, conditions or circumstances upon which any statement is based.

 

# # # #

Targeted Medical Pharma to Present at the Demy-Colton 2014 BIOTECH Showcase

Targeted Medical Pharma to Present at the Demy-Colton 2014 BIOTECH Showcase

Los Angeles, January 9, 2014 — Targeted Medical Pharma, announced that members of its executive team are scheduled to present the latest information regarding medical foods at the sixth annual Biotech Showcase™ on January 14, 2014 at 4:00 p.m. PST, at the Parc 55 Wyndham Hotel in San Francisco, CA. Management also will conduct one-on-one meetings with investors from January 13-15, 2014.

Biotech Showcase is an investor and partnering conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives at one of the industry’s largest annual healthcare investor conferences. The event is expected to attract 1,700 attendees from around the world. Targeted Medical Pharma is one of 230 companies selected to present at this year’s showcase.

About Targeted Medical Pharma, Inc.

Targeted Medical Pharma, Inc. is a Los Angeles-based biotechnology company that develops  medical foods for the treatment of chronic disease, including pain syndromes, peripheral neuropathy, hypertension, obesity, sleep and cognitive disorders. The company also develops a line of dietary supplements designed to support health and wellness.  The company manufactures 10 proprietary medical foods, and recently launched its first dietary supplement, Clearwayz™.  The products are sold directly to physicians and pharmacies in the U.S. The company also is developing nutrient-based systems for oral stimulation of progenitor stem cells that differentiate into neurons, red blood cells, pituitary hormones including IGF-I.

Forward Looking Statement

This press release may contain forward-looking statements related to Targeted Medical Pharma’s business strategy, outlook, objectives, plans, intentions or goals. The words “may,” “will,” “should,” “plans,” “explores,” “expects,” “anticipates,” “continue,” “estimate,” “project,” “intend,” and similar expressions, identify forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, but their absence does not mean that the statement is not forward-looking. These statements are not guarantees of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult to predict. Actual results could differ materially. Targeted Medical Pharma expressly disclaim any obligation or undertaking to update or revise any forward-looking statement contained herein to reflect any change in the company’s expectations with regard thereto or any change in events, conditions or circumstances upon which any statement is based.

# # # #